Assignee
CELLERANT THERAPEUTICS INC
US·14 granted patents·7 pending applications·84 citations·filing 2007–2021
Top patents by PatentIndex Score
21 records- 0195US8715619B2Compositions and methods for treating haematological proliferative disorders of myeloid originCELLERANT THERAPEUTICS INC·Filed 2013·Granted May 6, 2014·25 cites·18 claims
- 0294US9631026B2Antibodies that specifically bind to TIM3CELLERANT THERAPEUTICS INC·Filed 2014·Granted Apr 25, 2017·15 cites·12 claims
- 0391US9371390B2Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereofCELLERANT THERAPEUTICS INC·Filed 2014·Granted Jun 21, 2016·8 cites·13 claims
- 0488US9163090B2Antibodies specific for CLL-1CELLERANT THERAPEUTICS INC·Filed 2013·Granted Oct 20, 2015·13 cites·63 claims
- 0587US10898580B2IsoquinolidinobenzodiazepinesCELLERANT THERAPEUTICS INC·Filed 2018·Granted Jan 26, 2021·2 cites·20 claims
- 0687US9974864B2IsoquinolidinobenzodiazepinesCELLERANT THERAPEUTICS INC·Filed 2016·Granted May 22, 2018·6 cites·33 claims
- 0785US11072662B2Humanized anti-CLL-1 antibodiesCELLERANT THERAPEUTICS INC·Filed 2016·Granted Jul 27, 2021·2 cites·12 claims
- 0881US9504694B2IsoquinolidinobenzodiazepinesCELLERANT THERAPEUTICS INC·Filed 2016·Granted Nov 29, 2016·3 cites·30 claims
- 0981US8383095B2Methods and compositions for enhancing engraftment of hematopoietic stem cellsCELLERANT THERAPEUTICS INC·Filed 2007·Granted Feb 26, 2013·6 cites·13 claims
- 1076US10260044B1Methods of expanding myeloid cell populations and uses thereofCELLERANT THERAPEUTICS INC·Filed 2018·Granted Apr 16, 2019·1 cites·20 claims
- 1176US9850314B2Antibodies specific for CLL-1CELLERANT THERAPEUTICS INC·Filed 2015·Granted Dec 26, 2017·2 cites·27 claims
- 1275US2022064600A1Methods of expanding myeloid cell populations and uses thereofCELLERANT THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1371US10350218B2Isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimersCELLERANT THERAPEUTICS INC·Filed 2018·Granted Jul 16, 2019·1 cites·11 claims
- 1467US2014377234A1Methods of expanding myeloid cell populations and uses thereofCELLERANT THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 1564US10723805B2Antibodies specific for CLL-1CELLERANT THERAPEUTICS INC·Filed 2017·Granted Jul 28, 2020·0 cites·11 claims
- 1664US10301394B2Antibodies that specifically bind to TIM3CELLERANT THERAPEUTICS INC·Filed 2017·Granted May 28, 2019·0 cites·14 claims
- 1764US2019241872A1Methods of expanding myeloid cell populations and uses thereofCELLERANT THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1850US2020061079A1Isoquinolidinobenzodiazepine (iqb)-1(chloromethyl)-2,3-dihydro-1h-benzo[e]indole (cbi) dimersCELLERANT THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1947US2015315279A1Antibodies that bind membrane-bound il1rapCELLERANT THERAPEUTICS INC·Filed 2013·Application pending·0 cites
- 2043US2008003224A1Compositions and methods for treating haematological proliferative disordersCELLERANT THERAPEUTICS INC·Filed 2007·Application pending·0 cites
- 2140US2018312592A1Cysteine-substituted immunoglobulinsCELLERANT THERAPEUTICS INC·Filed 2016·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →